Afluria Quadrivalent Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of trivalent influenza vaccines, recurring multi-strain flu outbreaks, rising hospitalization rates from influenza, established immunization schedules, public sector vaccination programs.

The growth in the forecast period can be attributed to demand for broader strain coverage, increasing healthcare worker immunization, growth in pediatric vaccination programs, expansion of government procurement, innovation in vaccine delivery formats. Major trends in the forecast period include rising adoption of quadrivalent influenza vaccines, expanded protection against multiple flu strains, increased vaccination of high-risk populations, growth of government immunization initiatives, advancements in vaccine formulation technologies.

The rising prevalence of influenza is expected to drive the growth of the Afluria Quadrivalent market in the coming years. Influenza is a highly contagious respiratory infection caused by influenza viruses and can result in mild to severe symptoms, including fever, cough, and body aches. The increasing incidence of influenza is influenced by factors such as frequent viral mutations, seasonal climatic conditions, and insufficient vaccination coverage in certain population groups. Afluria Quadrivalent plays an important role in addressing the growing burden of influenza by offering protection against four circulating influenza strains, thereby lowering infection risk and reducing the severity of seasonal outbreaks. For example, in November 2024, according to the UK Health Security Agency, a UK-based government body, influenza positivity rates increased in week 46, with the weekly average reaching 3.9%, up from 3.3% in the previous week. The highest positivity rates were recorded among individuals aged 5 to 14 years, where the weekly average rose to 11.6% from 8.8% in week 45. As a result, the increasing prevalence of influenza is contributing to the growth of the Afluria Quadrivalent market.

Increasing birth rates are further expected to propel the growth of the Afluria Quadrivalent market. Growth in birth rates can be attributed to factors such as improved healthcare services, government incentives, and evolving societal attitudes. A higher number of births results in a larger pediatric population requiring routine immunization. As birth rates increase, healthcare systems must vaccinate more children to prevent influenza, leading to greater demand for vaccines such as Afluria Quadrivalent. For example, in October 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, 24,737 Aboriginal and Torres Strait Islander births were registered in 2023, representing an increase of 349 births compared to 2022. Consequently, rising birth rates are contributing to the growth of the Afluria Quadrivalent market.

The increase in healthcare expenditure is expected to propel the growth of the Afluria Quadrivalent market in the coming years. Healthcare expenditure refers to the total amount spent on medical services, treatments, and healthcare resources by governments, insurers, and individuals to ensure accessible and high-quality care. Rising healthcare spending supports the adoption of Afluria Quadrivalent, as higher funding levels enable wider access to seasonal influenza vaccination programs. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, representing a notable acceleration compared to the 0.9% growth recorded in 2022. Therefore, the rise in healthcare expenditure is contributing to the growth of the Afluria Quadrivalent market.

Major companies operating in the afluria quadrivalent market are Seqirus Inc.

North America was the largest region in the afluria quadrivalent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the afluria quadrivalent market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the afluria quadrivalent market by increasing costs for imported vaccine antigens, sterile vials, and cold-chain transportation services. These factors have influenced procurement costs for public and private immunization programs, especially in regions reliant on imported vaccines. Hospital, government supplier, and retail pharmacy segments in asia-pacific and latin america are among the most affected. Conversely, tariffs have encouraged domestic vaccine manufacturing, strengthened regional supply chains, and improved long-term vaccine security.

The afluria quadrivalent market research report is one of a series of new reports that provides afluria quadrivalent market statistics, including afluria quadrivalent industry global market size, regional shares, competitors with a afluria quadrivalent market share, detailed afluria quadrivalent market segments, market trends and opportunities, and any further data you may need to thrive in the afluria quadrivalent industry. This afluria quadrivalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Afluria Quadrivalent is a vaccine developed to prevent infection from four strains of the influenza virus, including two influenza A strains (H1N1 and H3N2) and two influenza B strains. It is intended to provide protection against influenza during the annual flu season. The vaccine is administered by injection and is approved for use in individuals aged six months and older.

The primary clinical indications of Afluria Quadrivalent include seasonal influenza prophylaxis, immunization of high-risk populations, pediatric influenza prevention, and healthcare worker immunization. Seasonal influenza prophylaxis refers to the preventive use of vaccines such as Afluria Quadrivalent to lower the risk of infection from circulating influenza strains. The routes of administration include injection and nasal spray. It is used across different age groups, including adults, geriatric, and pediatric populations, and is distributed through hospitals, retail pharmacies, government suppliers, and other channels. The end users include hospitals, public and private healthcare facilities, clinics, and others.

The afluria quadrivalent consists of sales of pre-filled syringes, vaccine vials, adjuvanted and unadjuvanted versions, flu vaccine kits, related packaging, and storage equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.